| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/29/2010 | WO2010047803A2 A method for the treatment of proliferative disorders of the eye |
| 04/29/2010 | WO2010047756A1 Oral dosage forms including an antiplatelet agents and an enterically coated acid inhibitor |
| 04/29/2010 | WO2010047737A2 Antimicrobial indoline compounds for treatment of bacterial infections |
| 04/29/2010 | WO2010047698A1 Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases |
| 04/29/2010 | WO2010047674A1 Low molecular weight thyroid stimulating hormone receptor (tshr) agonists |
| 04/29/2010 | WO2010047669A1 "cholvacor" - a medication in the form of liquid used for regulation of lipid exchange |
| 04/29/2010 | WO2010047663A1 Use of tocotrienol composition for the prevention of cancer |
| 04/29/2010 | WO2010047611A1 Process for preparing chlorins and their pharmaceutical uses |
| 04/29/2010 | WO2010047500A2 Composition for prevention or treatment of eye diseases |
| 04/29/2010 | WO2010047453A1 Pharmaceutical composition comprising cilnidipine and telmisartan |
| 04/29/2010 | WO2010047452A1 Pharmaceutical composition comprising lercanidipine and telmisartan |
| 04/29/2010 | WO2010047381A1 Stable tablet containing 4,5-epoxymorphinan derivative |
| 04/29/2010 | WO2010047372A1 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity |
| 04/29/2010 | WO2010047369A1 Agent for treatment of diabetic nephropathy |
| 04/29/2010 | WO2010047361A1 Pharmaceutical composition improved in absorption through intestinal tract |
| 04/29/2010 | WO2010047302A1 Combination nutritional infusion |
| 04/29/2010 | WO2010047295A1 Medicine for preventing or treating pain related to herpes zoster |
| 04/29/2010 | WO2010047216A1 METHOD FOR INHIBITING FUNCTION OF micro-RNA |
| 04/29/2010 | WO2010047127A1 PHENANTHROINDOLIZIDINE COMPOUND AND NFκB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT |
| 04/29/2010 | WO2010047126A1 PHENANTHROINDOLIZIDINE DERIVATIVE AND NFκB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT |
| 04/29/2010 | WO2010047120A1 PYRIDINE DERIVATIVE HAVING SUBSTITUTED HETERO RING AND SUBSTITUTED γ-GLUTAMYLAMINO GROUP, AND ANTI-FUNGAL AGENT COMPRISING SAME |
| 04/29/2010 | WO2010047108A1 Calicivirus inactivation method |
| 04/29/2010 | WO2010047103A1 Nfat signal inhibitor and hair-growing agent |
| 04/29/2010 | WO2010047094A1 Rotaxane compound and antitumor agent |
| 04/29/2010 | WO2010046931A2 Antifungal compounds containing benzothiazinone, benzoxazinone or benzoxazolinone and process thereof |
| 04/29/2010 | WO2010046917A2 Fludarabine phosphate composition |
| 04/29/2010 | WO2010046912A2 Thiophene containing analogues of fluconazole as antifungal agents and process thereof |
| 04/29/2010 | WO2010046910A1 Pharmaceutical compositions for the treatment of diabetes mellitus |
| 04/29/2010 | WO2010046889A1 Methods for delivery of sirna to bone marrow cells and uses thereof |
| 04/29/2010 | WO2010046869A2 Tetrahydronaphthalene compounds |
| 04/29/2010 | WO2010046861A1 Composition for treatment of epithelial tissue |
| 04/29/2010 | WO2010046857A1 Salts of isobutyric acid (1 r*, 2r*, 4r* ) -2- (2-{ [3- (4, 7-dimeth0xy-1 h-benzoimidazol-2-yl) -propyl] -methyl-amino } -ethyl) -5-phenyl-bicyclo [2.2.2] oct-5- en- 2 -yl |
| 04/29/2010 | WO2010046855A1 Bridged tetrahydronaphthalene derivatives |
| 04/29/2010 | WO2010046835A1 Crystalline forms of (r) -5- [3-chloro-4- ( 2, 3-dihydroxy-propoxy) -benz [z] ylidene] -2- ( [z] -propylimino) -3-0-tolyl-thiazolidin-4-one |
| 04/29/2010 | WO2010046780A2 Anti viral compounds |
| 04/29/2010 | WO2010046710A1 Therapeutics for neurological disorders |
| 04/29/2010 | WO2010046706A1 Treatment of inflammatory disorders |
| 04/29/2010 | WO2010046639A1 Fused pyridine derivatives as kinase inhibitors |
| 04/29/2010 | WO2010046540A1 Nucleic acid binding peptide |
| 04/29/2010 | WO2010046517A1 Compounds promoting the activity of mutant glycosidases |
| 04/29/2010 | WO2010046492A1 Biscuit comprising guar gum |
| 04/29/2010 | WO2010046462A1 Antibiotic synergism |
| 04/29/2010 | WO2010046458A2 Compositions comprising vitamins |
| 04/29/2010 | WO2010046445A2 Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use |
| 04/29/2010 | WO2010046418A1 Pharmaceutical composition comprising levetiracetam |
| 04/29/2010 | WO2010046401A1 Methods of using mevalonate decarboxylase (mvd) antagonists |
| 04/29/2010 | WO2010046399A1 Combinations for the treatment of migraine |
| 04/29/2010 | WO2010046388A1 Substituted (aza) -1-methyl-1h-quinolin-2-ones as antibacterials |
| 04/29/2010 | WO2010046375A1 Urea-based film-forming solution for treating nail psoriasis |
| 04/29/2010 | WO2010046360A1 Process for the preparation of substantially optically pure repaglinide and precursors thereof |
| 04/29/2010 | WO2010046321A1 Nutritional composition with anti-regurgitation properties |
| 04/29/2010 | WO2010046273A2 Pyrimidinyl pyridone inhibitors of jnk |
| 04/29/2010 | WO2010046239A1 Novel compound containing vanillin and ethylvanillin, and preparation and applications thereof |
| 04/29/2010 | WO2010046109A1 Pyrimidine and triazine sulfonamide derivates as b1 bradykinin receptor (b1r) inhibitors for treating pain |
| 04/29/2010 | WO2010046108A1 Substituted 4,5,6,7-tetrahydrothienopyridines as kcnq2/3 modulators for treating pain, epilepsy and urinary incontinence |
| 04/29/2010 | WO2010046048A1 Alkyl sulfosuccinate mixtures, and use thereof |
| 04/29/2010 | WO2010046035A1 Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine |
| 04/29/2010 | WO2010046034A1 Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine |
| 04/29/2010 | WO2010046013A1 Azaindole derivative |
| 04/29/2010 | WO2010045987A1 Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials |
| 04/29/2010 | WO2010045948A1 Isoquinolinone derivatives as nk3 antagonists |
| 04/29/2010 | WO2010045871A1 Composition and method for treating proteinuria |
| 04/29/2010 | WO2010045788A1 A orally disintegrating tablet of donepezil hydrochloride and the preparation method thereof |
| 04/29/2010 | WO2010045787A1 The use of ginsenoside compound k in the manufacture of atherosclerosis medicine |
| 04/29/2010 | WO2010045755A1 Glycosyl-derivatives of puerarin, pharmaceutical compositon, preparation method and use thereof |
| 04/29/2010 | WO2010045739A1 Process of producing directly compressed tablets of sterols and/or stanols |
| 04/29/2010 | WO2010045700A1 Method for preparing a veterinary suspension formulation for administering water-insoluble medicaments |
| 04/29/2010 | WO2010045682A1 Storage stable compositions and methods for preparing same |
| 04/29/2010 | WO2010045674A1 Methods for inducing programmed cell death |
| 04/29/2010 | WO2010027564A3 Amido anti-viral compounds, compositions, and methods of use |
| 04/29/2010 | WO2010023327A3 Method for obtaining oligonucleotide aptamers and uses thereof |
| 04/29/2010 | WO2010022031A8 Topical hydrogel composition |
| 04/29/2010 | WO2010020432A3 Compounds for treatment of duchenne muscular dystrophy |
| 04/29/2010 | WO2010018474A3 Novel glucopyranose derivatives, preparation thereof, and biological uses thereof |
| 04/29/2010 | WO2010017948A3 Pharmaceutical compositions of rivaroxaban with modified release properties |
| 04/29/2010 | WO2010017317A3 Use of mtor inhibitors to enhance t cell immune responses |
| 04/29/2010 | WO2010015335A8 Long-term treatment of symptomatic heart failure |
| 04/29/2010 | WO2010014814A3 Glycosylated warfarin analogs and uses thereof |
| 04/29/2010 | WO2010014253A3 Ant4 inhibitor compounds and methods of use thereof |
| 04/29/2010 | WO2010011856A3 Stereospecificity of methylsulfinyl reduction |
| 04/29/2010 | WO2010011772A3 Tri-cyclic pyrazolopyridine kinase inhibitors |
| 04/29/2010 | WO2010011541A3 Topical anti-inflammatory combination |
| 04/29/2010 | WO2010011312A9 Universal methylation profiling methods |
| 04/29/2010 | WO2010009014A3 Antibiotic drug |
| 04/29/2010 | WO2010008852A9 Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder |
| 04/29/2010 | WO2010007316A3 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 04/29/2010 | WO2010007232A4 Novel rapid-effect pharmaceutical forms and uses of resulting pharmaceutical compositions |
| 04/29/2010 | WO2010006267A3 Cyclic tetrapeptides |
| 04/29/2010 | WO2010006237A3 Phosphorothioate oligonucleotides non-nucleosidic phosphorothiotes as delivery agents for irna agents |
| 04/29/2010 | WO2010006189A3 Small-molecule inhibitors of hif and angiogenesis |
| 04/29/2010 | WO2010006129A3 2-methylene-(22e)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin d analogs |
| 04/29/2010 | WO2010005799A3 Novel acetates of 2-deoxy monosaccharides with anticancer activity |
| 04/29/2010 | WO2010003475A3 Novel pyrrolidone derivatives for use as metap-2 inhibitors |
| 04/29/2010 | WO2010003120A3 Antagonists of prostaglandin d2 receptors |
| 04/29/2010 | WO2009158719A3 Methods and compositions for treating disorders |
| 04/29/2010 | WO2009153428A3 Use of trilostane for treating depression |
| 04/29/2010 | WO2009150023A3 Method for producing sphingolipids by enzymatic n-acylation of lysosphingolipids using a lipase and a fatty acid glycerol ester |
| 04/29/2010 | WO2009150022A3 Method for producing sphingolipids by enzymatic n-acylation of lysosphingolipids using a fungal lipase and a fatty acid alkyl ester |
| 04/29/2010 | WO2009149785A8 Highly active antioxidant based on trehalulose |
| 04/29/2010 | WO2009143457A3 Vaccine composition containing synthetic adjuvant |